부산대학교 도서관

Introduction: Diabetic nephropathy is one of the leading causes of end-stage renal failure and a primary contributor to morbidity and mortality in patients with diabetes mellitus. Hyperuricemia is commonly observed in diabetic patients and is a risk factor for renal diseases. Various clinical studies have demonstrated that SGLT-2 inhibitors reduce SUA levels. Therefore, reducing SUA levels in patients with type 2 diabetes may prevent morbidity and mortality. Method: All data were analyzed using SPSS 25.0 software. Normality tests were performed for continuous variables. The mean/median values of the baseline and final values in the control and treatment groups were compared using the paired samples t-test and Wilcoxon test. The t-test and Mann-Whitney U tests were utilized to examine the mean/median change of parameters among the groups. Chi-square was used to evaluate the association between the categorical variables in groups. Statistical significance was defined as a p-value of 0.05. Results: In patients receiving SGLT treatment, there was a significant difference in the average values of weight, BMI, Ca, Mg, Cl, P, urea, creatinine, and GFR before and after treatment. In the control group, there was no significant difference between the mean values of parameters before and after treatment. When comparing the changes in parameters between the treatment and control groups, there was a statistically significant difference in weight, Ca, Mg, P, creatinine, and GFR changes between the two groups. Conclusion: There was a significant relationship between weight, Mg, P, and GFR changes in both the treatment and control groups. However, our study did not reveal statistically significant reductions in serum uric acid, proteinuria, albuminuria, HbA1c, and serum albumin levels. Conducting advanced studies with larger sample sizes and longer follow-up intervals may yield significant results. [ABSTRACT FROM AUTHOR]